Auranofin is a proteasomal deubiquitinase inhibitor with inhibition of the proteasome-associated deubiquitinases (DUBs) UCHL5 and USP14 rather than 20S proteasome, which is required for Auranofin-induced cytotoxicity. It selectively inhibits tumor growth in vivo and induces cytotoxicity in cancer cells from acute myeloid leukemia patients and by blocking NF-κB activation, Auranofin can attenuats the cardiac hypertrophy.